NeuroSense Therapeutics (NRSN) Share-based Compensation (2024 - 2025)
NeuroSense Therapeutics (NRSN) posted Share-based Compensation of $1.4 million for Q4 2025, up 3248.84% sequentially from $43000.0 in Q4 2024, and up 3248.84% YoY from $43000.0 in Q4 2024.
NeuroSense Therapeutics (NRSN) Share-based Compensation (2024 - 2025) Analysis & Trends
NeuroSense Therapeutics has reported Share-based Compensation for 2 years, with the latest figure at $1.4 million in Q4 2025.
- Quarterly Share-based Compensation rose 3248.84% year-over-year to $1.4 million in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $1.4 million (up 3248.84% YoY) and the FY2025 annual result came in at $2.1 million, up 221.8% from the prior year.
- Share-based Compensation climbed to $1.4 million in Q4 2025 per NRSN's latest filing, from $43000.0 in the prior quarter.
- Over five years, Share-based Compensation peaked at $1.4 million in Q4 2025 and troughed at $43000.0 in Q4 2024.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Stock Comp. (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 108.10 Mn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 243.00 Mn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | 120.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 137.41 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 86.63 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | 28.05 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 41.25 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | - |
| 10 | NeuroSense Therapeutics | 9.68 Mn | 9.47 Mn | - | 1.44 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 1.44 Mn |
| Dec 31, 2025 | 1.44 Mn |
| Dec 31, 2024 | 43,000.00 |
| Dec 31, 2024 | 43,000.00 |